This template was built with Webflow's free Prospero UI Kit. Learn more
If your child has recently been diagnosed with an SCN2A mutation, you are probably encountering a flood of unfamiliar words. Gene names, ion channels, variants, phenotypes — the language of genetics can feel like a foreign language when you are also trying to process difficult emotions and make decisions for your child. This guide is here to help.
Below, we explain what an SCN2A mutation is, why the specific type of mutation matters, what conditions are associated with it, and what a diagnosis means for your family going forward. Our goal is to give you a clear, honest, and hopeful foundation of knowledge — because understanding the science is one of the most powerful things you can do for your child.
Genes are the instruction sets encoded in our DNA. Every gene tells the body how to build a specific protein — a working part that the body needs to function. The SCN2A gene sits on chromosome 2 and contains the instructions for building a protein called Nav1.2, a type of sodium channel.
Sodium channels are tiny gateways found on the surface of brain cells (neurons). Their job is to allow sodium to flow in and out of cells at precisely the right moments, which creates the electrical signals that allow neurons to communicate with each other. Think of them as a carefully timed on-off switch for electrical activity in the brain.
Nav1.2 is one of the most important sodium channels in the developing brain. It plays a critical role in how brain cells fire, how signals travel between neurons, and how the brain learns and adapts over time.
To learn more about SCN2A and what it means for your family, visit our dedicated overview page.
A mutation — also called a pathogenic variant — is a change in the DNA sequence of a gene that disrupts how it works. When the SCN2A gene carries a pathogenic variant, the Nav1.2 sodium channel does not function normally. The electrical signaling in the brain is thrown off balance.
The consequences of this disruption depend significantly on the nature of the mutation itself. Not all SCN2A mutations cause the channel to malfunction in the same way — and this distinction has important implications for understanding a child's diagnosis and the direction of future care.
In most cases, SCN2A mutations occur de novo — meaning the change arises spontaneously for the first time in the child and was not inherited from either parent. Both parents typically test negative for the variant when genetic testing is performed. In a smaller number of cases, the variant is inherited from one parent.
One of the most important things caregivers can understand about an SCN2A diagnosis is that not all mutations work the same way. Researchers and clinicians classify SCN2A mutations into two broad functional categories, and this distinction matters greatly for understanding a child's condition.
Gain-of-function (GOF) mutations cause the Nav1.2 sodium channel to become overactive. The channel opens more than it should, flooding neurons with excessive electrical activity. This overactivity typically leads to early-onset seizures, often beginning in the first weeks or months of life. Children with GOF mutations are often diagnosed with early infantile epilepsy or Developmental and Epileptic Encephalopathy (DEE).
Loss-of-function (LOF) mutations have the opposite effect — the Nav1.2 sodium channel is underactive or produces fewer functional channels than normal. This reduction in electrical signaling is more often associated with autism spectrum disorder (ASD) and developmental differences, with or without seizures. In LOF cases, seizures — if they occur — tend to appear later.
Understanding which category a child's mutation falls into is not just academic. It has real clinical significance and should be discussed with a specialist who understands SCN2A-related disorders. Treatment approaches are tailored to the type and severity of each individual's presentation.
SCN2A mutations are associated with a range of neurological and developmental conditions. The specific presentation varies widely between individuals, even among those with similar mutations.
Epilepsy is one of the most common presentations associated with SCN2A mutations, particularly in children with GOF variants. Seizures may begin in the neonatal period (the first four weeks of life) or during infancy. Some children experience seizures that are difficult to control with medication; others may have seizure types that are milder or respond well to treatment. In some cases, particularly with certain variant types, seizures resolve by the age of two.
SCN2A has been identified as one of the leading single-gene causes of autism spectrum disorder (ASD). Children with SCN2A-related ASD often show early signs such as limited eye contact, delayed speech development, and differences in social interaction. Many are described as engaged with their caregivers in their own way, even when verbal communication is limited.
Many children with SCN2A mutations experience some degree of developmental difference, ranging from mild delays to more significant intellectual disability. Areas that may be affected include speech and language development, motor skills, memory, and learning. Every child's developmental profile is unique.
Some individuals with SCN2A mutations experience movement-related challenges, including low muscle tone (hypotonia), difficulty with coordination, or episodic movement abnormalities. These are less common than seizures or developmental differences but are an important part of the full clinical picture.
The foundation is working to advance SCN2A research and emerging therapies that address the full range of SCN2A-related conditions.
An SCN2A mutation is identified through genetic testing. The most common pathway is a gene panel test or whole exome sequencing (WES) — a type of genetic analysis that reads the instructions in a person's DNA to look for variants that may be causing their symptoms.
Genetic testing is typically ordered by a pediatric neurologist, geneticist, or genetic counselor after a child presents with unexplained seizures, developmental delay, or autism. Many families receive a diagnosis after months or even years of searching for answers, which is why the SCN2A Foundation advocates strongly for early and accessible genetic testing.
Once a variant is identified, a genetic counselor can help interpret the result — explaining what the specific variant likely means, whether it is classified as gain-of-function or loss-of-function, and what is known about its associated phenotype (the clinical picture it tends to cause).
A diagnosis is the beginning of a new chapter — one that comes with a name, a direction, and a community. For many families, receiving an SCN2A diagnosis after months of uncertainty brings a complex mix of grief and relief. The name does not change your child, but it can change what is possible for their care.
SCN2A-related disorders are rare, but they are not alone in the landscape of rare genetic conditions, and the research community around SCN2A has grown significantly in recent years. Care for children with SCN2A mutations is typically multidisciplinary, involving neurologists, developmental pediatricians, speech and occupational therapists, and behavioral health specialists working together.
The SCN2A Foundation exists to make sure no family has to navigate this path alone. Connect with the SCN2A Foundation community to find support, resources, and connection with other families who understand.
This is one of the most exciting moments in the history of SCN2A research. Scientists now have a significantly deeper understanding of how SCN2A mutations work, how they differ from one another, and what that means for developing targeted therapies.
Researchers are actively exploring approaches including precision therapies designed to address the specific functional impact of individual SCN2A variants. The genotype-phenotype correlation in SCN2A — meaning the relatively predictable relationship between the type of mutation and the clinical presentation — makes it a compelling target for precision medicine approaches.
Clinical studies, natural history registries, and drug development pipelines are actively progressing. Families who register with research programs and participate in natural history studies contribute directly to the scientific knowledge base that will shape the next generation of treatments.
Every family navigating an SCN2A diagnosis deserves answers, access to emerging research, and real hope for the future. There are two powerful ways to be part of the work that moves us forward. Sign up to stay connected and ensure your family is part of the network shaping what comes next. And if you are able, please consider making a donation to help fund the research and resources that bring us all closer to answers.
Medical Disclaimer: This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
3. Children's Hospital of Philadelphia — SCN2A-Related Disorders
4. Simons Searchlight — SCN2A Gene Guide (2024)
7. NORD — National Organization for Rare Disorders
Share
If your child has recently been diagnosed with an SCN2A mutation, you are probably encountering a flood of unfamiliar words. Gene names, ion channels, variants, phenotypes — the language of genetics can feel like a foreign language when you are also trying to process difficult emotions and make decisions for your child. This guide is here to help.
Below, we explain what an SCN2A mutation is, why the specific type of mutation matters, what conditions are associated with it, and what a diagnosis means for your family going forward. Our goal is to give you a clear, honest, and hopeful foundation of knowledge — because understanding the science is one of the most powerful things you can do for your child.
Genes are the instruction sets encoded in our DNA. Every gene tells the body how to build a specific protein — a working part that the body needs to function. The SCN2A gene sits on chromosome 2 and contains the instructions for building a protein called Nav1.2, a type of sodium channel.
Sodium channels are tiny gateways found on the surface of brain cells (neurons). Their job is to allow sodium to flow in and out of cells at precisely the right moments, which creates the electrical signals that allow neurons to communicate with each other. Think of them as a carefully timed on-off switch for electrical activity in the brain.
Nav1.2 is one of the most important sodium channels in the developing brain. It plays a critical role in how brain cells fire, how signals travel between neurons, and how the brain learns and adapts over time.
To learn more about SCN2A and what it means for your family, visit our dedicated overview page.
A mutation — also called a pathogenic variant — is a change in the DNA sequence of a gene that disrupts how it works. When the SCN2A gene carries a pathogenic variant, the Nav1.2 sodium channel does not function normally. The electrical signaling in the brain is thrown off balance.
The consequences of this disruption depend significantly on the nature of the mutation itself. Not all SCN2A mutations cause the channel to malfunction in the same way — and this distinction has important implications for understanding a child's diagnosis and the direction of future care.
In most cases, SCN2A mutations occur de novo — meaning the change arises spontaneously for the first time in the child and was not inherited from either parent. Both parents typically test negative for the variant when genetic testing is performed. In a smaller number of cases, the variant is inherited from one parent.
One of the most important things caregivers can understand about an SCN2A diagnosis is that not all mutations work the same way. Researchers and clinicians classify SCN2A mutations into two broad functional categories, and this distinction matters greatly for understanding a child's condition.
Gain-of-function (GOF) mutations cause the Nav1.2 sodium channel to become overactive. The channel opens more than it should, flooding neurons with excessive electrical activity. This overactivity typically leads to early-onset seizures, often beginning in the first weeks or months of life. Children with GOF mutations are often diagnosed with early infantile epilepsy or Developmental and Epileptic Encephalopathy (DEE).
Loss-of-function (LOF) mutations have the opposite effect — the Nav1.2 sodium channel is underactive or produces fewer functional channels than normal. This reduction in electrical signaling is more often associated with autism spectrum disorder (ASD) and developmental differences, with or without seizures. In LOF cases, seizures — if they occur — tend to appear later.
Understanding which category a child's mutation falls into is not just academic. It has real clinical significance and should be discussed with a specialist who understands SCN2A-related disorders. Treatment approaches are tailored to the type and severity of each individual's presentation.
SCN2A mutations are associated with a range of neurological and developmental conditions. The specific presentation varies widely between individuals, even among those with similar mutations.
Epilepsy is one of the most common presentations associated with SCN2A mutations, particularly in children with GOF variants. Seizures may begin in the neonatal period (the first four weeks of life) or during infancy. Some children experience seizures that are difficult to control with medication; others may have seizure types that are milder or respond well to treatment. In some cases, particularly with certain variant types, seizures resolve by the age of two.
SCN2A has been identified as one of the leading single-gene causes of autism spectrum disorder (ASD). Children with SCN2A-related ASD often show early signs such as limited eye contact, delayed speech development, and differences in social interaction. Many are described as engaged with their caregivers in their own way, even when verbal communication is limited.
Many children with SCN2A mutations experience some degree of developmental difference, ranging from mild delays to more significant intellectual disability. Areas that may be affected include speech and language development, motor skills, memory, and learning. Every child's developmental profile is unique.
Some individuals with SCN2A mutations experience movement-related challenges, including low muscle tone (hypotonia), difficulty with coordination, or episodic movement abnormalities. These are less common than seizures or developmental differences but are an important part of the full clinical picture.
The foundation is working to advance SCN2A research and emerging therapies that address the full range of SCN2A-related conditions.
An SCN2A mutation is identified through genetic testing. The most common pathway is a gene panel test or whole exome sequencing (WES) — a type of genetic analysis that reads the instructions in a person's DNA to look for variants that may be causing their symptoms.
Genetic testing is typically ordered by a pediatric neurologist, geneticist, or genetic counselor after a child presents with unexplained seizures, developmental delay, or autism. Many families receive a diagnosis after months or even years of searching for answers, which is why the SCN2A Foundation advocates strongly for early and accessible genetic testing.
Once a variant is identified, a genetic counselor can help interpret the result — explaining what the specific variant likely means, whether it is classified as gain-of-function or loss-of-function, and what is known about its associated phenotype (the clinical picture it tends to cause).
A diagnosis is the beginning of a new chapter — one that comes with a name, a direction, and a community. For many families, receiving an SCN2A diagnosis after months of uncertainty brings a complex mix of grief and relief. The name does not change your child, but it can change what is possible for their care.
SCN2A-related disorders are rare, but they are not alone in the landscape of rare genetic conditions, and the research community around SCN2A has grown significantly in recent years. Care for children with SCN2A mutations is typically multidisciplinary, involving neurologists, developmental pediatricians, speech and occupational therapists, and behavioral health specialists working together.
The SCN2A Foundation exists to make sure no family has to navigate this path alone. Connect with the SCN2A Foundation community to find support, resources, and connection with other families who understand.
This is one of the most exciting moments in the history of SCN2A research. Scientists now have a significantly deeper understanding of how SCN2A mutations work, how they differ from one another, and what that means for developing targeted therapies.
Researchers are actively exploring approaches including precision therapies designed to address the specific functional impact of individual SCN2A variants. The genotype-phenotype correlation in SCN2A — meaning the relatively predictable relationship between the type of mutation and the clinical presentation — makes it a compelling target for precision medicine approaches.
Clinical studies, natural history registries, and drug development pipelines are actively progressing. Families who register with research programs and participate in natural history studies contribute directly to the scientific knowledge base that will shape the next generation of treatments.
Every family navigating an SCN2A diagnosis deserves answers, access to emerging research, and real hope for the future. There are two powerful ways to be part of the work that moves us forward. Sign up to stay connected and ensure your family is part of the network shaping what comes next. And if you are able, please consider making a donation to help fund the research and resources that bring us all closer to answers.
Medical Disclaimer: This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
3. Children's Hospital of Philadelphia — SCN2A-Related Disorders
4. Simons Searchlight — SCN2A Gene Guide (2024)
7. NORD — National Organization for Rare Disorders
Vlad Magdalin
